Endovascular Engineering (E2) announced today that it raised $42 million in an oversubscribed Series B financing round.

ANTICOAGULANT treatment is winning for itself a firm place in the armamentarium against postoperative venous thrombosis and pulmonary embolism. This has been accomplished by the sheer weight of ...

Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its n ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE).

The global premature ejaculation (PE) treatment market is projected to grow by $1.53b by 2029 at a compound annual growth rate of 8.6%, according to Technavio. The sector’s expansion is driven ...

Acute pulmonary embolism is rare during childhood and adolescence. The high pulmonary embolism-related fatality among ...

"I am incredibly excited to be involved in this study as it represents a significant milestone in the forward trajectory of pulmonary embolism treatment." The QUADRA-PE study is a multi-center ...

Akura Medical begins patient enrollment in QUADRA-PE study of Katana Thrombectomy System to treat acute pulmonary embolism: Los Gatos, California Thursday, February 6, 2025, 18:00 ...